Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–20.

Article  PubMed  Google Scholar 

Yoon M, Hong N, Ha J, Lee CJ, Ku CR, Rhee Y, et al. Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea. Hypertens Res. 2022;45:1418–29.

Article  CAS  PubMed  Google Scholar 

Xu Z, Yang J, Hu J, Song Y, He W, Luo T, et al. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol. 2020;75:1913–22.

Article  CAS  PubMed  Google Scholar 

Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173:10–20.

Article  PubMed  PubMed Central  Google Scholar 

Byrd JB, Turcu AF, Auchus RJ. Primary aldosteronism: practical approach to diagnosis and management. Circulation. 2018;138:823–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu YY, King J, Kline GA, Padwal RS, Pasieka JL, Chen G, et al. Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism. JAMA Surg. 2021;156:541–9.

Article  PubMed  Google Scholar 

Cohen JB, Bancos I, Brown JM, Sarathy H, Turcu AF, Cohen DL. Primary aldosteronism and the role of mineralocorticoid receptor antagonists for the heart and kidneys. Annu Rev Med. 2023;74:217–30.

Article  CAS  PubMed  Google Scholar 

Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41–50.

Article  CAS  PubMed  Google Scholar 

Monticone S, Sconfienza E, D’Ascenzo F, Buffolo F, Satoh F, Sechi LA, et al. Renal damage in primary aldosteronism: a systematic review and meta-analysis. J Hypertens. 2020;38:3–12.

Article  CAS  PubMed  Google Scholar 

Qian N, Xu J, Wang Y. Stroke Risks in primary aldosteronism with different treatments: a systematic review and meta-analysis. J Cardiovasc Dev Dis. 2022;9:300.

PubMed  PubMed Central  Google Scholar 

Chen SY, Chen JY, Huang WC, Puar THK, Chin Kek P, Chueh JS, et al. Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis. Eur J Endocrinol. 2022;187:S47–S58.

Article  CAS  PubMed  Google Scholar 

Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–916.

Article  CAS  PubMed  Google Scholar 

Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J. 2022;69:327–59.

Article  PubMed  Google Scholar 

Nishikawa T, Satoh F, Takashi Y, Yanase T, Itoh H, Kurihara I, et al. Comparison and commutability study between standardized liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) and chemiluminescent enzyme immunoassay for aldosterone measurement in blood. Endocr J. 2022;69:45–54.

Article  CAS  PubMed  Google Scholar 

Teruyama K, Naruse M, Tsuiki M, Kobayashi H. Novel chemiluminescent immunoassay to measure plasma aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism. J Hum Hypertens. 2022;36:77–85.

Article  CAS  PubMed  Google Scholar 

Ozeki Y, Tanimura Y, Nagai S, Nomura T, Kinoshita M, Shibuta K, et al. Development of a New Chemiluminescent Enzyme Immunoassay Using a Two-Step Sandwich Method for Measuring Aldosterone Concentrations. Diagnostics (Basel). 2021;11:433.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kobayashi H, Nakamura Y, Abe M, Tanabe A, Sone M, Katabami T, et al. Impact of a change to a novel chemiluminescent immunoassay for measuring plasma aldosterone on the diagnosis of primary aldosteronism. Endocr J. 2023;70:489–500.

Article  CAS  PubMed  Google Scholar 

Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, et al. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr J. 2011;58:711–21.

Article  CAS  PubMed  Google Scholar 

Satoh F, Morimoto R, Seiji K, Satani N, Ota H, Iwakura Y, et al. Is there a role for segmental adrenal venous sampling and adrenal sparing surgery in patients with primary aldosteronism? Eur J Endocrinol. 2015;173:465–77.

Article  CAS  PubMed  Google Scholar 

Fukumoto T, Umakoshi H, Ogata M, Yokomoto-Umakoshi M, Matsuda Y, Motoya M, et al. Significance of Discordant Results Between Confirmatory Tests in Diagnosis of Primary Aldosteronism. J Clin Endocrinol Metab. 2021;106:e866–e874.

Article  PubMed  Google Scholar 

Eisenhofer G, Peitzsch M, Kaden D, Langton K, Pamporaki C, Masjkur J, et al. Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. Clin Chim Acta. 2017;470:115–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin Y, Ma C, Yu S, Ai Q, Han C, Zhong J, et al. Reference intervals for LC-MS /MS measurements of plasma renin activity, aldosterone, angiotensin II, and 24-hour urinary aldosterone in Northern Chinese Han population. Clin Chim Acta. 2023;543:117325.

Article  CAS  PubMed  Google Scholar 

Guo Z, Poglitsch M, McWhinney BC, Ungerer JPJ, Ahmed AH, Gordon RD, et al. Aldosterone LC-MS/MS Assay-Specific Threshold Values in Screening and Confirmatory Testing for Primary Aldosteronism. J Clin Endocrinol Metab. 2018;103:3965–73.

Article  PubMed  Google Scholar 

Brown JM, Auchus RJ, Honzel B, Luther JM, Yozamp N, Vaidya A. Recalibrating Interpretations of Aldosterone Assays Across the Physiologic Range: Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry Measurements Under Multiple Controlled Conditions. J Endocr Soc. 2022;6:bvac049.

Article  PubMed  PubMed Central  Google Scholar 

Kwon SY, Park J, Park SH, Cho SH, Lee YB, Lee SY, et al. Aldosterone Immunoassay-Specific Cutoff Value for Seated Saline Suppression Test for Diagnosing Primary Aldosteronism. Endocrinol Metab (Seoul). 2022;37:938–42.

Article  CAS  PubMed  Google Scholar 

Fuss CT, Brohm K, Kurlbaum M, Hannemann A, Kendl S, Fassnacht M, et al. Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. Eur J Endocrinol. 2021;184:167–78.

Article  CAS  PubMed  Google Scholar 

Eisenhofer G, Kurlbaum M, Peitzsch M, Constantinescu G, Remde H, Schulze M, et al. The saline infusion test for primary aldosteronism: implications of immunoassay inaccuracy. J Clin Endocrinol Metab. 2022;107:e2027–e2036.

Article  PubMed  Google Scholar 

Morimoto R, Ono Y, Tezuka Y, Kudo M, Yamamoto S, Arai T, et al. Rapid screening of primary aldosteronism by a novel chemiluminescent immunoassay. Hypertension. 2017;70:334–41.

Article  CAS  PubMed  Google Scholar